



For release at 5:00 PM ET on Sunday, May 7, 2006

Contact:

Christopher Thurman, +1 (404) 601-1430, ext. 1419

RFS Pharma Announces Appointment of Dr. Steven J. Coats as Senior Director of Chemistry

Tucker, GA, May 7, 2006--RFS Pharma, LLC today announced the appointment of Dr. Steven J. Coats to the position of Senior Director of Chemistry. Dr. Coats has more than 10 years of drug discovery and development experience in biotech and large pharmaceutical companies. Prior to joining RFS Pharma, Dr. Coats was Principal Scientist at Johnson and Johnson Pharmaceutical Research and Development, LLC in Spring House, Pennsylvania with responsibility for discovery project management and synthetic medicinal chemistry spanning numerous therapeutic areas. He also directed an analytical/purification group and parallel synthesis scientists. At RFS Pharma, Dr. Coats will be responsible for directing the company's chemistry program in the development of proprietary molecules for the treatment of infections caused by HIV-1 and hepatitis viruses, inflammatory conditions, and cancer.

"Dr. Steven Coats' leadership and knowledge of drug discovery processes will ensure that RFS Pharma maintains a robust pipeline and innovative edge," said Dr. Raymond F. Schinazi, Founder and Director of RFS Pharma.

Before joining Johnson and Johnson, Dr. Coats served as group leader for focused library synthesis at Helios Pharmaceuticals where he was responsible for design, synthesis and optimization of novel small molecules. In a period of three years he personally prepared or directed the synthesis of more than 35,000 new compounds.

Dr. Coats received his Ph.D. in chemistry from Emory University (under Professor Albert Padwa) in Atlanta, Georgia. He was a post-doctoral associate at Yale University (under Professor Harry H. Wasserman), has co-authored numerous research publications in peer reviewed journals and is co-inventor on 19 issued or pending patents.

About RFS Pharma, LLC

RFS Pharma, LLC, was founded in September 2004 and is located in a 26,500 sq. ft. state-of-the-art research facility in Tucker, Georgia. RFS Pharma is a privately owned biotech company committed to the discovery and development of antiviral agents and other human therapeutics. The company capitalizes on its expertise in nucleoside chemistry to develop drugs to combat infections caused by drug-resistant HIV and hepatitis viruses, as well as developing drugs to treat inflammation and cancer. RFS Pharma's lead product candidate is amdoxovir[®] (DAPD, AMDX), which is in Phase 2 clinical trials for the treatment of HIV-1 and HBV under a US IND. For further information about RFS Pharma, please refer to <http://www.rfspharma.com>

Forward-looking Statements

"Safe Harbor" Statement: Any statements in this press release that relate to the Company's expectations are forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995. Since this information may involve risks and uncertainties and be subject to change at any time, the Company's actual results may differ materially from expected results. The Company disclaims any obligation to update the statements contained in this Company press release.

SOURCE: RFS Pharma, LLC

#####